Marksans Pharma rose 3.3% Monday after its UK subsidiary Relonchem received MHRA approval to market Metformin Hydrochloride Prolonged Release Tablets (500 mg, 750 mg, 1000 mg). The drug, widely used for type 2 and gestational diabetes, improves insulin sensitivity and lowers blood sugar. The approval boosts Marksans' UK presence, though the stock remains down ~40% YTD.